Potassium Citrate

Potassium citrate occupies a unique position in the supplement landscape because it is one of the few over-the-counter supplements that is also first-line prescription therapy for a common medical condition. Urologists routinely prescribe potassium citrate for recurrent calcium oxalate and uric acid kidney stone formers, and the supplement form provides the same active compound at lower doses. But this medical legitimacy comes with genuine risks that most supplement buyers do not understand. Potassium citrate is not a casual “alkalizing” or “detox” supplement — it is a pharmacologically active mineral salt that can cause life-threatening hyperkalemia in susceptible individuals.

The mechanism for stone prevention is well established. Citrate binds to calcium in urine, forming soluble calcium-citrate complexes that remain in solution rather than crystallizing into calcium oxalate stones. Simultaneously, the potassium alkalinizes urine, raising pH from the acidic range (where uric acid stones form) toward neutral. Pak’s 2002 trial in the American Journal of Kidney Diseases demonstrated that potassium citrate significantly reduced stone recurrence in calcium oxalate stone formers while increasing urinary citrate excretion — the key biomarker for stone protection.

The blood pressure benefit is supported by large-scale evidence. Aburto’s 2013 meta-analysis in the BMJ, pooling data from 22 RCTs and 1,606 participants, found that increased potassium intake reduced systolic blood pressure by 3.49 mmHg and diastolic by 2.44 mmHg, with a 24% reduction in stroke risk. The effect was strongest in people with hypertension and those with high sodium intake. Potassium citrate provides this benefit while also delivering the stone-prevention effects of citrate — a dual advantage over potassium chloride supplements.

The bone health mechanism is less well known but equally important. High dietary acid load (from protein-rich, low-vegetable diets) increases bone resorption as the body mobilizes calcium from bone to buffer systemic acid. Potassium citrate neutralizes this acid load, reducing urinary calcium excretion and bone turnover markers. Sellmeyer’s 2006 trial showed that potassium citrate reduced urinary calcium and bone resorption markers in postmenopausal women compared to potassium chloride, suggesting that the citrate component has bone-protective effects beyond just the potassium.

The honest framing must center on safety. Potassium citrate is contraindicated in chronic kidney disease (CKD) because impaired renal potassium excretion leads to hyperkalemia — elevated blood potassium that can cause fatal cardiac arrhythmias. It is also dangerous when combined with ACE inhibitors, ARBs, potassium-sparing diuretics (spironolactone, amiloride), and NSAIDs, all of which reduce potassium excretion. The elderly, people with diabetes, and those with reduced kidney function are at highest risk. Hyperkalemia often has no symptoms until cardiac arrest occurs.

Practical guidance: For kidney stone prevention, the medical dose is typically 20–30 mEq (approximately 780–1,170 mg) of potassium citrate daily, split into 2–3 doses, under urological supervision. Over-the-counter supplements typically provide 99–300 mg per capsule — lower than prescription doses but potentially useful for mild stone formers or those seeking blood pressure support. Take with meals to reduce GI irritation. If you have any kidney disease, take ACE inhibitors, ARBs, or potassium-sparing diuretics, consult a physician before use. Monitor serum potassium if using long-term. In India, potassium citrate is available from Healthvit, HealthyHey, and Now Foods.